|By PR Newswire||
|February 26, 2014 12:36 PM EST||
LONDON, Feb. 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria
Since their discovery almost a century ago, antibiotics have revolutionized the global healthcare industry by ushering in an era of significantly reduced morbidity and mortality associated with often-lethal bacterial infections. However, the increasing threat posed by multidrug-resistant (MDR) bacteria, in particular gram-negative organisms, has cast a shadow over these remarkable public health achievements. GlobalData's primary research indicates that this high level of unmet need has generated several opportunities for firms seeking access to the market in the US or 5EU. Public and private entities have also launched initiatives to make antibiotic R&D an attractive therapy area. GlobalData anticipates that a mixture of push, pull, and hybrid mechanisms will encourage progress through all stages of antibiotic development. Increased flexibility from the FDA and EMA is also expected to decrease barriers to entry for drugs targeting MDR gram-negative bacteria. GlobalData believes that a partnership approach, involving academia, small and medium enterprises, and Big Pharma, is the best strategy for companies hoping to leverage these incentives to gain access to the market.
Key Questions Answered
- What are the main unmet needs associated with treating drug-resistant gram-negative bacterial infections?
- What opportunities can companies exploit to gain access to the US and 5EU markets?
- What incentive mechanisms and programs can companies leverage to fund their antibiotic R&D?
- How is the changing regulatory landscape at the FDA and EMA going to affect the review of antibiotics for MDR gram-negative bacterial infections?
- What advantages does the public-private partnership approach to antibiotic R&D have over the traditional business plan for antibiotics?
- The escalating need for therapies against MDR gram-negative bacteria has created opportunities that can be leveraged to enter the marketplace in both the US and 5EU.
- Incentive initiatives, such as the Generating Antibiotics Incentives Now (GAIN) Act, are making antibiotics an attractive therapy area.
- The FDA and EMA have both expressed and demonstrated a willingness to increase their flexibility regarding clinical trial design and endpoints.
- The partnership approach to antibiotic R&D, which involves collaboration between academia, small and medium enterprises, and Big Pharma, is replacing the solo approach traditionally used by companies.
- Overview of incentive mechanisms and programs designed to encourage antibiotic R&D, current regulatory trends, and the role of academia, small and medium enterprises and Big Pharma in bringing next-generation antibiotics to market.
- Key topics covered include unmet needs, opportunities, and the emergence of public-private partnerships in the market for antibiotics targeting multidrug-resistant gram-negative bacteria.
- Analysis of the key industry drivers, restraints and challenges in the US and 5EU. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design your market access strategy through a review of clinical and commercial unmet needs as well as regulatory trends related to gram-negative antibiotics.
- Develop business strategies by understanding the trends shaping and driving the gram-negative antibiotics market in the US and 5EU.
- Drive revenues by understanding the key trends and opportunities likely to impact the US and 5EU gram-negative antibiotics markets.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 11
3 Market Drivers and Barriers 12
3.1 Overview 12
3.2 Drivers 14
3.2.1 Driver: Increase in the Incidence of MDR Gram-Negative Bacterial Infections 14
3.2.2 Driver: Higher Pricing of Novel Antibiotics 15
3.2.3 Driver: A Rising Awareness of the Need for Novel Antibiotics 17
3.2.4 Driver: Economic Incentive Programs for Antibiotic Development 18
3.2.5 Driver: Regulatory Reform and Clinical Trial Redesign 19
3.2.6 Driver: Publically-Funded Resources or Partnerships (PPPs) 21
3.2.7 Driver: Improved Diagnostic Tools 22
3.2.8 Driver: Efforts to Decrease Overall Healthcare Costs 24
3.3 Barriers 25
3.3.1 Barrier: Low ROI Compared with Other Therapy Areas 25
3.3.2 Barrier: Difficulty Developing Truly Novel Antibiotics 26
3.3.3 Barrier: Antibiotic Stewardship 28
3.3.4 Barrier: Limited Awareness of the Threat Posed by Drug-Resistant Bacteria 29
3.3.5 Barrier: Convoluted, Shifting Regulatory Requirements 31
3.3.6 Barrier: Regulatory Bureaucracy 32
3.3.7 Barrier: Cost-Conscious Governments 34
3.3.8 Barrier: Movement Towards Preventative Care 35
3.3.9 Barrier: Competition from Cheap, Generally-Effective Generics 36
4 Unmet Needs Assessment and Opportunity Analysis 38
4.1 Unmet Needs Overview 38
4.1.1 Unmet Need: Antibiotics that Treat MDR Gram-Negative Infections 40
4.1.2 Unmet Need: Antibiotics with Novel Mechanisms of Action Targeted at Specific Pathogens 41
4.1.3 Unmet Need: Accurate, Rapid, and Inexpensive Diagnostic Tools 43
4.1.4 Unmet Need: Increase Awareness of the Threat Posed by Antibiotic Resistance 45
4.1.5 Unmet Need: Streamlined Treatment Guidelines or Global Approaches to Combat Resistance 47
4.2 Opportunities Overview 49
4.2.1 Opportunity: Screen Molecules in an Environment Similar to the Infection Site 51
4.2.2 Opportunity: Biologicals as Antibiotics 52
4.2.3 Opportunity: Leveraging Novel Diagnostics to Achieve and Maintain Commercial Success 54
4.2.4 Opportunity: Enhancing the Activity of Existing Antibiotics Against MDR Infections 55
4.2.5 Opportunity: Probiotics and Natural Flora 56
5 Incentives for Antibiotic Development 58
5.1 Overview 58
5.2 Push Incentives 61
5.2.1 Overview 61
5.2.2 Advantages 63
5.2.3 Disadvantages 63
5.3 Pull Incentives 65
5.3.1 Overview 65
5.3.2 Advantages 67
5.3.3 Disadvantages 67
5.4 Combination and Hybrid Incentives 69
5.4.1 Overview 69
5.4.2 Advantages 70
5.4.3 Disadvantages 71
6 Current Regulatory Trends 72
6.1 Overview of Regulatory Trends 72
6.1.1 Increased Pragmatism Regarding Clinical Trial Endpoints 76
6.1.2 Recognition of Preclinical-Clinical Activity Correlation (PK/PD) 78
6.1.3 Escalating Value of Microbiological Diagnostics 79
6.1.4 More Practical Risk-Benefit Assessment 80
6.1.5 Establishing an FDA-EMA Regulatory Accord for Antibiotics 82
7 The Need for an Alternative Approach to Antibiotic R&D 84
7.1 Overview 84
7.1.1 The Traditional Approach 84
7.1.2 The Partnership Approach 86
7.2 Stakeholders 89
7.2.1 The Role of Big Pharma 89
7.2.2 The Role of Academia and SMEs 91
7.2.3 The Role of Government 94
8 Appendix 97
8.1 Bibliography 97
8.2 Abbreviations 104
8.3 Physicians and Specialists Included in this Study 107
8.4 About the Authors 111
8.4.1 Authors 111
8.4.2 Reviewer 112
8.4.3 Global Head of Healthcare 112
8.5 About GlobalData 113
8.6 Disclaimer 113
List of Tables
Table 1: MDR Gram-Negative Infections – Drivers and Barriers, 2013 13
Table 2: 6MM Unmet Needs – Current Level of Attainment 39
Table 3: Push Incentives Overview 61
Table 4: Pull Incentives Overview 66
Table 5: Hybrid Incentives Overview 69
Table 6: Role of Big Pharma in Antibiotic R&D 90
Table 7: Role of Academic and SME Entities in Antibiotic R&D 92
Table 8: Role of Government Agencies in Antibiotic R&D 95
List of Figures
Figure 1: Opportunity Analysis – Clinical and Commercial Impact 50
Figure 2: Outline of Push and Pull Incentives for Antibiotic Development 59
Figure 3: Regulatory Trends in Antibiotic Drug Development 74
Figure 4: Traditional and Partnership Business Models in Antibiotic R&D 87
Read the full report:
PharmaFocus: Market Access Strategies for Antibiotics Targeting Multidrug-Resistant Gram-Negative Bacteria
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Jan. 19, 2017 06:30 PM EST Reads: 6,313
Providing secure, mobile access to sensitive data sets is a critical element in realizing the full potential of cloud computing. However, large data caches remain inaccessible to edge devices for reasons of security, size, format or limited viewing capabilities. Medical imaging, computer aided design and seismic interpretation are just a few examples of industries facing this challenge. Rather than fighting for incremental gains by pulling these datasets to edge devices, we need to embrace the i...
Jan. 19, 2017 05:30 PM EST Reads: 3,625
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Jan. 19, 2017 05:15 PM EST Reads: 1,292
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
Jan. 19, 2017 05:15 PM EST Reads: 3,099
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Jan. 19, 2017 04:45 PM EST Reads: 3,755
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
Jan. 19, 2017 04:45 PM EST Reads: 3,470
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jan. 19, 2017 04:15 PM EST Reads: 5,405
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
Jan. 19, 2017 04:00 PM EST Reads: 5,427
SYS-CON Events announced today that Catchpoint, a leading digital experience intelligence company, has been named “Silver Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Catchpoint Systems is a leading Digital Performance Analytics company that provides unparalleled insight into your customer-critical services to help you consistently deliver an amazing customer experience. Designed for digital business, C...
Jan. 19, 2017 03:45 PM EST Reads: 1,792
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, will highlight the current challenges of these transformative technologies and share strategies for preparing your organization for these changes. This “view from the top” will outline the latest trends and developm...
Jan. 19, 2017 03:30 PM EST Reads: 1,033
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
Jan. 19, 2017 02:15 PM EST Reads: 1,057
@ThingsExpo has been named the ‘Top WebRTC Influencer' by iTrend. iTrend processes millions of conversations, tweets, interactions, news articles, press releases, blog posts - and extract meaning form them and analyzes mobile and desktop software platforms used to communicate, various metadata (such as geo location), and automation tools. In overall placement, @ThingsExpo ranked as the number one ‘WebRTC Influencer' followed by @DevOpsSummit at 55th.
Jan. 19, 2017 02:00 PM EST Reads: 4,782
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Jan. 19, 2017 01:15 PM EST Reads: 5,670
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Jan. 19, 2017 01:15 PM EST Reads: 5,162
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Jan. 19, 2017 01:15 PM EST Reads: 3,532